Soleno Therapeutics is currently navigating a transition from a clinical-stage entity to a potential commercial player, though its recent financial performance is heavily distorted by non-recurring milestone payments. While the company reported a net income of...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 7, 2026 | $0.59-19.2% vs $0.73 | $95M+0.9% vs $94M |
Q1 2026 Feb 25, 2026 | $0.80+25.0% vs $0.64 | $92M+3.4% vs $89M |
Q4 2025 Nov 4, 2025 | $0.47+717.4% vs $0.06 | $66M-25.4% vs $89M |
Q3 2025 Aug 6, 2025 | -$0.09+83.0% vs -$0.53 | $33M-17.0% vs $39M |
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Soleno Therapeutics, Inc. (NASDAQ: SLNO) breached their fiduciary duties to shareholders.
Benchmark SLNO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Soleno Therapeutics, Inc. (SLNO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $53.01 | $2.76B | 135.92 | — | 10.97% | 6.01% | — | |
| $14.88 | $1.47B | -2.55 | 20.13% | -81.79% | — | — | |
| $25.43 | $4.35B | 11.10 | 11.87% | 33.42% | 32.39% | — | |
| $98.24 | $6.74B | -31.59 | 45.83% | -85.59% | -80.48% | — | |
| $513.02 | $11.83B | -39.92 | 432.05% | -25.32% | -56.65% | — | |
| $62.34 | $5.17B | 8.01 | 114.51% | -3.8% | — | — |
Soleno Therapeutics, Inc. (SLNO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Soleno Therapeutics, Inc. (SLNO) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 18, 2026·SEC
Apr 7, 2026·SEC
Apr 6, 2026·SEC
Get notified when SLNO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Soleno Therapeutics, Inc. (SLNO) stock FAQ — growth, dividends, profitability & financials explained
Soleno Therapeutics, Inc. (SLNO) reported $285.0M in revenue for fiscal year 2025.
Yes, Soleno Therapeutics, Inc. (SLNO) is profitable, generating $96.0M in net income for fiscal year 2025 (11.0% net margin).
Soleno Therapeutics, Inc. (SLNO) has a return on equity (ROE) of 6.0%. This is below average, suggesting room for improvement.
Soleno Therapeutics, Inc. (SLNO) generated $105.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
